GRN1005: Phase II started

Geron began the open-label, U.S. Phase II GRABM-L trial to evaluate 650 mg/m 2 IV GRN1005 every 3 weeks in about 50 NSCLC patients with brain metastases. Geron is also evaluating the compound in the P...